Circulating endothelial cells are elevated in patients with type 1 diabetes mellitus

Ebru Asicioglu1, Dilek Gogas Yavuz2, Mehmet Koc1, Beste Ozben1, Dilek Yazici2, Oguzhan Deyneli2, and Sema Akalin2

1Division of Nephrology, Department of Internal Medicine, 2Division of Endocrinology and Metabolism, Department of Internal Medicine and 3Department of Cardiology, Marmara University School of Medicine, Tophanelioglu Cadess, No: 15/10, Altunizade, Uskudar, Istanbul 32622, Turkey

(Correspondence should be addressed to E Asicioglu; Email: easicioglu@yahoo.com)

Abstract

Objective: Circulating endothelial cells (CECs) have emerged as vascular damage markers and are increased in type 2 diabetic patients. Since type 1 diabetes is associated with vascular damage, we hypothesized high CEC numbers in this patient population.

Methods: Thirty-nine patients with type 1 diabetes and 39 controls were included. CECs were isolated using anti-CD146-coated Dynabeads, stained with Ulex lectin-1, and counted by fluorescence microscopy. Endothelial function was measured as flow-mediated dilation (FMD). Thiobarbituric acid reactive substances (TBARS), total glutathione levels (GSH), and paraoxonase (PON) activity levels were measured as oxidative stress markers.

Results: Patients with type 1 diabetes mellitus had higher number of CECs (7.46 ± 5.37 vs 2.13 ± 1.13 cells/ml, P < 0.001), lower FMD (7.87 ± 2.19 vs 12.06 ± 2.34%, P < 0.001), higher TBARS (4.94 ± 1.20 vs 3.07 ± 0.75 nmol/MDA, P < 0.001), lower GSH (206.12 ± 98.06 vs 353.61 ± 68.45 μM, P < 0.001), and lower PON activity levels (89.10 ± 17.82 vs 127.65 ± 29.01 U/l, P < 0.001) as compared to controls. There was positive correlation between CEC numbers and HbAlc levels (r = 0.49, P = 0.002). CECs and fasting glucose levels were not correlated. There was no correlation between the number of CECs and FMD. Furthermore, there were no correlations between the number of CECs and TBARS, GSH and PON activity levels. Multiple regression analysis showed that HbAlc levels (r² = 0.40, P < 0.009) were associated with CEC numbers.

Conclusion: CECs are elevated in patients with type 1 diabetes mellitus reflecting endothelial damage. This increase is dependent on long-term glucose control.

European Journal of Endocrinology 162 711–717

Introduction

Endothelial dysfunction has been documented in patients with diabetes and plays a key role in the pathogenesis of diabetic vascular disease, which is the principal cause of mortality and morbidity in these patients (1–5). Hypertension and hyperlipidema are some of the well-known risk factors for the development of endothelial dysfunction. However, hyperglycemia itself can cause endothelial injury and dysfunction through several mechanisms (6–12). Exposure of endothelial cells to high glucose levels increases oxidative stress. This results in enhanced generation of reactive oxygen species and reduction of antioxidant reserves (13–16). Hyperglycemia also increases the production of advanced glycation end products as well as the activation of the protein kinase C and polyol pathways (13–16). These hyperglycemia-mediated mechanisms disrupt cell cycling, which in turn causes inhibition of cell proliferation and migration as well as an increase in the apoptosis of endothelial cells (17–21).

In recent years, circulating endothelial cells (CECs) have emerged as markers of vascular damage. While present in very small numbers in healthy individuals, their number increases dramatically in diseases with vascular damage, such as cardiovascular disease, specific infections, vasculitis, and type 2 diabetes (22–29). Since type 1 diabetes is associated with endothelial dysfunction and vascular damage, we hypothesized increased number of CECs in this patient population. We measured the number of CECs, flow-mediated dilation (FMD), and oxidative stress markers thiobarbituric acid reactive substances (TBARS), total glutathione levels (GSH), and serum paraoxonase (PON) activity in type 1 diabetes and healthy subjects. We further attempted to determine the correlation between the number of CECs and markers of endothelial dysfunction, oxidative stress and glucose control.
Methods

Patients and controls

The study was approved by the ethics committee of Marmara University Medical School and was carried out in accordance with the Declaration of Helsinki. All subjects gave informed consent for participation. Thirty-nine type 1 diabetic patients and healthy controls were included in the study. Inclusion criteria for the diabetic group were previous diagnosis of type 1 diabetes for at least 1 year and age between 18 and 60 years. Healthy individuals with normal fasting blood glucose levels who were at least 18 years old were included as the control group. Exclusion criteria for both groups were as follows: i) any systemic disease that is known to cause endothelial dysfunction such as systemic hypertension (defined according to the JNC-7 criteria), hyperlipidemia (defined according to the NCEP-ATP3 criteria), coronary artery disease, peripheral vascular disease, carotid artery disease, inflammatory or infectious processes within the last 3 months, and malignancy (30, 31), ii) invasive procedures within the last month, iii) abnormal renal/hepatic biochemical values, iv) medications that can disrupt endothelial function such as aspirin, antilipemic agents, angiotensin converting enzyme (ACE) inhibitors, and angiotensin receptor blockers (ARBs), v) smoking, and vi) pregnancy and lactation.

Isolation and enumeration of CECs

In order to isolate and enumerate CECs, we used the study protocol described by Woywodt et al. (32). This technique depends on the use of paramagnetic particles coated with antibodies directed against the CD146 molecule found on endothelial cells.

Blood was obtained by nontraumatic venipuncture and collected in two 7.5 ml EDTA tubes. The first tube was discarded to avoid false positive results caused by dislodging of endothelial cells during venipuncture. One milliliter of blood from the second tube was diluted in 1 ml BSA/PBS buffer (0.1% BSA in PBS) and blocked by 20 μl Fc receptor (Miltenyi, Gladbach, Germany) for 10 min at 4 °C. Then, 50 μl anti-CD146-coated M-450 paramagnetic particles (Dynabeads, Dynal, Norway) were added and mixed thoroughly. The sample was mixed in a head-over-head mixer for 30 min at 4 °C and washed four times with PBS/BSA buffer in front of a magnet (Dynal, MPC-L, Dynal, Norway). Then, these isolated cells are further stained with a specific endothelial cell marker. Fifty microliters of a 2 mg/ml FITC-coupled UEA-1 solution (Sigma–Aldrich) were added and incubated for half an hour in darkness. Then, the sample was washed twice and suspended in 200 μl PBS solution. Cells were counted by fluorescence microscopy using a Nageotte chamber (Fig. 1). CECs were identified according to the criteria defined by Woywodt et al. Cells that were 20–50 μm in length and covered with at least four magnetic beads staining positive with FITC-UEA-1 were accepted as endothelial cells (32). To serve as positive controls, various concentrations of human umbilical vein endothelial cells were diluted in blood from healthy volunteers, and recovery was > 90%.

Measurement of FMD

High-resolution ultrasound was used to assess changes in the diameter of the brachial artery. Measurements were taken in the fasting state before obtaining blood samples with the subjects resting for at least 10 min in the supine position. Images were obtained by a single operator using a 10-MHz vascular ultrasound probe (Vingmed Ultrasound, System 5, Horten, Norway). The brachial artery was scanned 10–15 cm above the antecubital fossa, and the transducer was kept in a fixed position throughout the procedure. After baseline measurements of the diameter and the flow velocity of the brachial artery, a blood pressure cuff placed around the forearm was inflated to 300 mmHg and released after 5 min. The diameter and the flow velocity were measured again 45–60 s after cuff release. Then, the brachial artery was allowed to return to baseline values over a period of 15 min for the measurement of endothelium-independent dilation. In order to measure endothelium-independent dilation, 400 μg sublingual glyceryl trinitrate (GTN) was applied, and the measurements were repeated after 3 min. Percent FMD and percent GTN were calculated as the percent changes in diameter relative to the baseline measurements.
Measurements were done at end diastole simultaneously with the R-wave on a continuously recorded electrocardiogram. The diameters at three cardiac cycles were analyzed for each measurement, and the average value was used. The intra-observer variability was < 5%.

**Measurement of TBARS**

Lipid peroxidation was measured by the formation of TBARS using 1,1,3,3-tetraethoxypropane as standard. After the serum was mixed with thiobarbituric acid, it was heated at 100 °C for 15 min. The red pigment produced was extracted with n-butanol–pyridine mixture and was estimated by absorbance at 532 nm (33). Intra- and interassay coefficients of variation were 4.8 and 5.1% respectively.

**Measurement of PON activity**

The PON activity was determined spectrophotometrically using paraoxon as the substrate in a Tris buffer containing NaCl and CaCl₂ and measured by increases in the absorbance at 405 nm due to the formation of 4-nitrophenol. After the addition of the serum sample, the reaction was monitored for 5 min at 25 °C, and PON activity was expressed as units per liter of serum (U/l) (34).

**Measurement of GSH**

GSH was measured in blood plasma as described by Hu et al. (35). Plasma was mixed with Tris–EDTA and measured at an absorbance of 412 nm. This value was called A1. Then, di-thiobis nitrobenzoic acid was added to the mixture and incubated for 15 min in the darkness. This was again measured at an absorbance of 412 nm, yielding A2. The GSH was calculated from the formula (A2 − A1) × 1.57 and expressed as μM.

**Statistical analysis**

All calculations were done using SPSS for Windows version 11.0 (SPSS, Chicago, IL, USA). Data were expressed as means ± S.D. Comparisons between the groups were done by Mann–Whitney U test. Spearman’s rank correlation analysis was utilized to determine the relation between the number of CECs and markers of endothelial dysfunction, oxidative stress and glucose control. Stepwise multiple regression analysis was performed to define the predictors of CEC number, and P < 0.05 was considered statistically significant at all times.

**Results**

Demographic and clinical features of study groups are summarized in Tables 1–3.

---

**Table 1** Demographic characteristics of patients and healthy controls. Values are expressed as mean ± s.d.

<table>
<thead>
<tr>
<th></th>
<th>Type 1 diabetic patients (n=39)</th>
<th>Healthy controls (n=39)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age (years)</strong></td>
<td>31.74 ± 8.53</td>
<td>29.23 ± 4.64</td>
</tr>
<tr>
<td><strong>Gender (F/M)</strong></td>
<td>15/24</td>
<td>26/13</td>
</tr>
<tr>
<td><strong>Duration of diabetes (years)</strong></td>
<td>9.27 ± 6.12</td>
<td>–</td>
</tr>
<tr>
<td><strong>Retinopathy</strong></td>
<td>2/39</td>
<td>–</td>
</tr>
<tr>
<td><strong>Nephropathy</strong></td>
<td>4/39</td>
<td>–</td>
</tr>
<tr>
<td><strong>Neuropathy</strong></td>
<td>2/39</td>
<td>–</td>
</tr>
<tr>
<td><strong>BMI (kg/m²)</strong></td>
<td>24.23 ± 3.12</td>
<td>22.93 ± 2.79</td>
</tr>
<tr>
<td><strong>Waist-to-hip ratio</strong></td>
<td>0.80 ± 0.05</td>
<td>0.80 ± 0.07</td>
</tr>
<tr>
<td><strong>Systolic BP (mmHg)</strong></td>
<td>109.76 ± 19.86</td>
<td>109.32 ± 8.18</td>
</tr>
<tr>
<td><strong>Diastolic BP (mmHg)</strong></td>
<td>72.90 ± 9.05</td>
<td>77.70 ± 4.50*</td>
</tr>
</tbody>
</table>

BMI, body mass index; BP, blood pressure. *P<0.05 versus type 1 diabetic patients group.

Age, body mass index, waist-to-hip ratio, and systolic blood pressure measurements were similar between the two groups. The number of female controls was significantly higher compared to diabetic patients. While diastolic blood pressure measurements were statistically different between the two groups, they were still within the normal range (Table 1). Fasting glucose and HbAlc values are significantly higher in the diabetic group. Total cholesterol, low density lipoprotein cholesterol, high density lipoprotein cholesterol, triglycerides, and creatinine values are not statistically different between the two groups (Table 2).

Patients with type 1 diabetes mellitus had higher CECs (7.46 ± 5.37 cells/ml) compared to healthy controls (2.13 ± 1.13 cells/ml; P < 0.001). FMD (%) was significantly lower in the diabetic group (7.87 ± 2.19 vs 12.06 ± 2.34, P < 0.001). Patients with type 1 diabetes had higher TBARS levels (4.94 ± 1.20 vs 3.07 ± 0.75 nmol/MDA, P < 0.001), lower GSH levels (206.12 ± 98.06 vs 353.61 ± 68.45 μM, P < 0.001), and lower PON activity (89.10 ± 17.82 vs 127.65 ± 29.01 U/l, P < 0.001) compared to healthy controls (Table 3).

There were negative correlations between FMD (%) and fasting glucose (r = −0.40, P < 0.001), HbAlc (r = −0.56, P < 0.001) and TBARS levels (r = −0.68, P < 0.001). There were significant positive correlations between duration of diabetes and HbAlc (r = 0.56, P < 0.001) and LDL cholesterol (r = 0.44, P < 0.001).

---

**Table 2** Biochemical data of study groups. Values are expressed as mean ± s.d.

<table>
<thead>
<tr>
<th></th>
<th>Type 1 diabetic patients (n=39)</th>
<th>Healthy controls (n=39)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Fasting glucose (mg/dl)</strong></td>
<td>181.75 ± 98.16</td>
<td>83.68 ± 12.86*</td>
</tr>
<tr>
<td><strong>HbAlc (%)</strong></td>
<td>7.42 ± 1.69</td>
<td>4.58 ± 0.31*</td>
</tr>
<tr>
<td><strong>Total cholesterol (mg/dl)</strong></td>
<td>151.89 ± 44.47</td>
<td>145.35 ± 45.66</td>
</tr>
<tr>
<td><strong>LDL cholesterol (mg/dl)</strong></td>
<td>95.63 ± 31.55</td>
<td>93.97 ± 35.13</td>
</tr>
<tr>
<td><strong>HDL cholesterol (mg/dl)</strong></td>
<td>37.00 ± 10.99</td>
<td>38.51 ± 11.28</td>
</tr>
<tr>
<td><strong>Triglycerides (mg/dl)</strong></td>
<td>81.37 ± 44.68</td>
<td>64.14 ± 29.47</td>
</tr>
<tr>
<td><strong>Creatinine (mg/dl)</strong></td>
<td>0.92 ± 0.26</td>
<td>0.91 ± 0.17</td>
</tr>
</tbody>
</table>

*P<0.001 versus type 1 diabetic patients group.
The number of CECs and HbAlc levels (r = 0.49, P = 0.002; Fig. 2). However, CEC numbers and fasting glucose levels were not correlated. There was no correlation between the number of CECs and FMD. Furthermore, there were no correlations between the number of CECs and markers of oxidative stress, measured as TBARS levels, GSH levels, and PON activity (data not shown). Multiple regression analysis showed that HbAlc levels (r² = 0.40, P < 0.009) were associated with CEC numbers.

Discussion

In recent years, measurement of CECs has emerged as a new method of determining endothelial function. While present in very small numbers in healthy individuals, their number increases dramatically in diseases with vascular damage, such as cardiovascular diseases, vasculitis, hemodialysis patients, specific infections, and type 2 diabetes (22–29, 36). Furthermore, these numbers correlate with disease activity and are closely related to the severity of endothelial lesions (27, 28). In this study, we found that patients with type 1 diabetes mellitus had a significantly increased number of CECs as compared to healthy controls. Furthermore, the CEC numbers were positively correlated with HbAlc levels.

Prolonged hyperglycemia impairs endothelial cell function, resulting in endothelial dysfunction. Our results were in accordance with this, showing a strong correlation between the number of CECs and the levels of HbAlc. To our knowledge, this is the first study to show a correlation between CEC numbers and HbAlc levels. In another study by McClung et al., they showed an increase in the number of CECs in type 2 diabetic patients but were not able to show a correlation with the levels of HbAlc (29). We believe that this was due to the patient population studied. The incidence of coronary artery disease, hypertension, and hyperlipidemia is higher in type 2 diabetic patients, all having the potential to cause endothelial dysfunction and increased CEC numbers (23, 37, 38). Furthermore, patients using ACE inhibitors and statins, medications known to alter endothelial function, were included. Patients with type 2 diabetes mellitus also have insulin resistance, which contributes to inflammation, and this inflammation-mediated endothelial dysfunction is substantially less likely to be correlated with HbAlc. In this study, we excluded patients with known hypertension, hyperlipidemia, or coronary artery disease. Patients taking medications known to affect endothelial function were further excluded. We believe that the increase in CEC numbers in our study reflects endothelial dysfunction solely caused by hyperglycemia and therefore is correlated with the levels of HbAlc.

In our study, diabetic patients had higher TBARS levels as well as lower GSH, PON activity, and percent FMD as compared to healthy controls, which is consistent with previous reports in literature (6, 39–41). FMD (%) showed negative correlation with fasting glucose, HbAlc, and TBARS levels, while positively correlated with GSH and PON activity levels. Our data show that endothelial dysfunction measured as percent FMD and oxidative stress coexist in diabetes and are closely related. However, there were no correlations between CEC numbers and TBARS, GSH, PON activity and percent FMD. We believe that this shows that the increase in CEC number in this patient population may be a direct consequence of the effect of hyperglycemia on vasculature such as increased endothelial cell apoptosis and sloughing rather than endothelial damage caused by oxidative stress. Several studies have shown that hyperglycemia increases endothelial cell apoptosis through the production of peroxynitrate (17, 20). Hyperglycemia also prolongs endothelial cell cycle and inhibits proliferation (19, 21, 42). Lorenzi et al. have shown that chronic hyperglycemia but not acute hyperglycemia prolongs the endothelial cell cycle (19). This may explain why CEC numbers in our study were correlated with HbAlc levels, while fasting glucose levels were not correlated. Hyperglycemia-induced oxidative stress also increases detachment of the endothelial cells from the extracellular matrix, which probably contributes to increased CEC numbers in diabetic patients (43). Another possible mechanism for increased endothelial cell sloughing may be the heme oxygenase (HO) system. Abraham et al. have shown that

### Table 3 Measurements of CECs, FMD, TBARS, GSH, and PON.

<table>
<thead>
<tr>
<th></th>
<th>Type 1 diabetic patients (n = 39)</th>
<th>Healthy controls (n = 39)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of CECs (cells/ml)</td>
<td>7.46 ± 5.37</td>
<td>2.13 ± 1.13*</td>
</tr>
<tr>
<td>FMD (%)</td>
<td>7.87 ± 2.19</td>
<td>12.06 ± 3.24*</td>
</tr>
<tr>
<td>TBARS (nmol/MDA)</td>
<td>4.94 ± 1.20</td>
<td>3.07 ± 0.75*</td>
</tr>
<tr>
<td>GSH (μM)</td>
<td>206.12 ± 98.06</td>
<td>353.61 ± 68.45*</td>
</tr>
<tr>
<td>PON (U/l)</td>
<td>89.10 ± 17.82</td>
<td>127.65 ± 29.01*</td>
</tr>
</tbody>
</table>

CECs, circulating endothelial cells; FMD, flow-mediated dilatation; TBARS, thiobarbituric acid reactive substances; GSH, total glutathione levels; PON, serum paraoxonase activity. *P < 0.001 versus type 1 diabetic patients group.

between FMD (%) and GSH (r = 0.51, P < 0.001) as well as PON activity levels (r = 0.62, P < 0.001).
the number of detached endothelial cells increases in diabetic rats and in hyperglycemic animals underexpressing HO-1, while decreasing in diabetic animals overexpressing HO-1 compared with controls (44). All these studies show that hyperglycemia, through several different mechanisms, decreases growth and migration of endothelial cells, while enhancing apoptosis and cell sloughing (17–21, 42–44).

In this study, the number of CECs in the diabetic cohort is less than those reported in patients with type 2 diabetes mellitus and other inflammatory conditions. There are several possible explanations for this discrepancy. Even though a consensus has been reached in enumerating CECs with immunomagnetic isolation, some studies have used different techniques with this method (23, 26, 32). There are also studies that count CECs with flow cytometry (22). Another possible explanation is the association between disease activity, inflammation, endothelial lesions, and CEC number. In a recent study, patients with active anti-neutrophil cytoplasmic antibody (ANCA)-positive granulomatous vasculitis had significantly higher CEC numbers as compared to those with limited disease or remission (45). Similarly, other studies have reported a correlation between CEC numbers, and markers of inflammation and endothelial dysfunction such as C-reactive protein (CRP) and von Willebrand factor (vWF). Since acute myocardial infarction, unstable angina, vasculitis, and infections are associated with more inflammation than diabetes mellitus, it may be safe to assume a smaller number of CECs in this patient population. Patients with type 2 diabetes mellitus have a higher incidence of coronary artery disease, hypertension, and hyperlipidemia as compared to type 1 diabetic patients as well as insulin resistance, all having the potential to cause more inflammation, endothelial dysfunction, and thus higher CEC numbers (23, 37, 38). Insulin resistance observed in type 2 diabetic patients may also account for greater endothelial damage and higher CEC numbers in this population.

Even though CECs are increased in certain conditions, it is not clear whether this increase is due to endothelial cell sloughing caused by vascular damage or an increase in endothelial progenitor cells derived from the bone marrow. However, we know that at least in hyperglycemic states, endothelial cell apoptosis and cell sloughing increase. Furthermore, prior studies have demonstrated decreased numbers of bone marrow-derived circulating endothelial progenitor cells in conditions associated with endothelial dysfunction (46, 47). Therefore, it is logical to assume that the increase in CEC number is due to endothelial cell sloughing caused by vascular damage.

CECs are not merely markers of ongoing endothelial damage; they are also predictors of future cardiovascular events in certain patient populations (48, 49). The value of CECs predicting future cardiovascular events in diabetic patients is unknown. The close relationship between oxidative stress markers and CEC number may support this notion in diabetic patients. In the future, a much larger prospective study can be designed to determine whether the increase in CEC number is indicative of an adverse outcome in this patient population. Bone marrow-derived circulating progenitor cells can be measured by flow cytometry in the same patient population in order to determine the origin of CECs with certainty.

In conclusion, we have demonstrated that the number of CECs is elevated in patients with type 1 diabetes reflecting endothelial damage, and this increase is also directly dependent on long-term glucose control.

Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding
This work was supported by grants from ‘Eczacıbaşı Scientific Research and Award Fund’ and ‘The Marmara University Scientific Research Committee’.

References

www.eje-online.org


39 Jain SK & McVie R. Effect of glycemic control, race (white versus black), and duration of diabetes on reduced glutathione content in arterial cells. American Journal of Medicine 1993 95 469–475.

40 Jain SK & McVie R. Effect of glycemic control, race (white versus black), and duration of diabetes on reduced glutathione content in arterial cells. American Journal of Medicine 1993 95 469–475.

41 Jain SK & McVie R. Effect of glycemic control, race (white versus black), and duration of diabetes on reduced glutathione content in arterial cells. American Journal of Medicine 1993 95 469–475.


www.eje-online.org


Received 28 November 2009
Accepted 29 December 2009